{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:51:18Z","timestamp":1761745878383},"reference-count":80,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Whether response to an interleukin (IL-17) inhibitor is different in patients with previous exposure to an IL-17 inhibitor compared with patients with exposure to biologics with other cytokine targets remains to be elucidated. Therefore, the aim of this study was to\u00a0 assess whether previous exposure to an IL-17A inhibitor was associated with worse response than exposure to (an)other biologic(s). All patients in the DERMBIO register treated with an IL-17A inhibitor (secukinumab or ixekizumab) were included. With an absolute Psoriasis Area and Severity Index (PASI) \u2264 2 as response, the proportion of responders treated with IL-17A inhibitors was assessed in patients previously treated with another IL-17A inhibitor and compared with patients with previous exposure to (an)other biologic(s), using a \u03c72 test. In total, 100, 93 and 83 patients with\u00a0 previous exposure to an IL-17A inhibitor and 414, 372 and 314 patients with previous exposure to (an) other biologic(s) were assessed after 3, 6 and 12 months, respectively. No differences in the proportion of\u00a0 patients achieving PASI \u2264 2 were observed between the 2 groups after 3 months (54% vs 57%, p = 0.59), 6months (70% vs 66%, p = 0.42) and 12 months (69% vs 60%, p = 0.14). In conclusion, when treating patients with IL-17A inhibitors the cytokine target of the previous biologic does not appear to affect the\u00a0 response.<\/jats:p>","DOI":"10.2340\/actadv.v103.12616","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T13:52:46Z","timestamp":1700574766000},"page":"adv12616","source":"Crossref","is-referenced-by-count":5,"title":["Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study"],"prefix":"10.2340","volume":"103","author":[{"given":"Nikolai","family":"Loft","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Isufi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads K.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars E.","family":"Bryld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas N.","family":"Dam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kawa K.","family":"Ajgeiy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trine","family":"Bertelsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lone","family":"Skov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"42150","doi-asserted-by":"crossref","unstructured":"Cui L, Chen R, Subedi S, Yu Q, Gong Y, Chen Z, et al. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol 2018; 62: 46-58.","DOI":"10.1016\/j.intimp.2018.06.020"},{"key":"42151","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.intimp.2018.06.020","DOI":"10.1016\/j.intimp.2018.06.020"},{"key":"42152","doi-asserted-by":"crossref","unstructured":"Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJ. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12\/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatol Treat 2018; 29: 569-578.","DOI":"10.1080\/09546634.2017.1422591"},{"key":"42153","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2017.1422591","DOI":"10.1080\/09546634.2017.1422591"},{"key":"42154","doi-asserted-by":"crossref","unstructured":"Loft N, Vaengebjerg S, Halling AS, Skov L, Egeberg A. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Dermatol Venereol 2020; 34: 1151-1160.","DOI":"10.1111\/jdv.16073"},{"key":"42155","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16073","DOI":"10.1111\/jdv.16073"},{"key":"42156","doi-asserted-by":"crossref","unstructured":"Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Daud\u00e9n E, S\u00e1nchez-Carazo J-L, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 2012; 148: 463-470.","DOI":"10.1001\/archdermatol.2011.2768"},{"key":"42157","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/archdermatol.2011.2768","DOI":"10.1001\/archdermatol.2011.2768"},{"key":"42158","doi-asserted-by":"crossref","unstructured":"Ger T-Y, Huang Y-H, Hui RC-y, Tsai T-F, Chiu H-Y. Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. Ther Adv Chronic Dis 2019; 10: 2040622319843756.","DOI":"10.1177\/2040622319843756"},{"key":"42159","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/2040622319843756","DOI":"10.1177\/2040622319843756"},{"key":"42160","doi-asserted-by":"crossref","unstructured":"Notario J, Deza G, Vilarrasa E, Valent\u00ed F, Mu\u00f1oz C, Mollet J, et al. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. J Dermatol Treat 2019; 30: 424-429.","DOI":"10.1080\/09546634.2018.1528000"},{"key":"42161","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2018.1528000","DOI":"10.1080\/09546634.2018.1528000"},{"key":"42162","doi-asserted-by":"crossref","unstructured":"Galluzzo M, Talamonti M, De Simone C, D'Adamio S, Moretta G, Tambone S, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther 2018; 18: 727-735.","DOI":"10.1080\/14712598.2018.1481503"},{"key":"42163","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/14712598.2018.1481503","DOI":"10.1080\/14712598.2018.1481503"},{"key":"42164","doi-asserted-by":"crossref","unstructured":"Chiricozzi A, Burlando M, Caldarola G, Conti A, Damiani G, De Simone C, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol 2020; 21: 441-447.","DOI":"10.1007\/s40257-019-00490-2"},{"key":"42165","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-019-00490-2","DOI":"10.1007\/s40257-019-00490-2"},{"key":"42166","doi-asserted-by":"crossref","unstructured":"Megna M, Di Costanzo L, Argenziano G, Balato A, Colasanti P, Cusano F, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther 2019; 19: 855-861.","DOI":"10.1080\/14712598.2019.1622678"},{"key":"42167","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/14712598.2019.1622678","DOI":"10.1080\/14712598.2019.1622678"},{"key":"42168","doi-asserted-by":"crossref","unstructured":"Schwarz CW, Loft N, Rasmussen MK, Nissen CV, Dam TN, Ajgeiy KK, et al. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish nationwide cohort study. Acta Derm Venereol 2021; 101: adv00579.","DOI":"10.2340\/actadv.v101.351"},{"key":"42169","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/actadv.v101.351","DOI":"10.2340\/actadv.v101.351"},{"key":"42170","doi-asserted-by":"crossref","unstructured":"Loft N, Egeberg A, Rasmussen M, Bryld L, Nissen C, Dam T, et al. Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study. J Eur Acad Dermatol Venereol 2022; 36: 1284-1291.","DOI":"10.1111\/jdv.18126"},{"key":"42171","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.18126","DOI":"10.1111\/jdv.18126"},{"key":"42172","doi-asserted-by":"crossref","unstructured":"Loft N, Halling A-S, Egeberg A, Skov L. Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: a systematic review and meta-analysis. J Am Acad Dermatol 2021; 84: 130-138.","DOI":"10.1016\/j.jaad.2020.07.085"},{"key":"42173","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.07.085","DOI":"10.1016\/j.jaad.2020.07.085"},{"key":"42174","doi-asserted-by":"crossref","unstructured":"Bokor-Billmann T, Sch\u00e4kel K. No need to change the drug class: ixekizumab-following secukinumab-therapy in psoriasis. J Dermatol Treat 2019; 30: 216-220.","DOI":"10.1080\/09546634.2018.1506081"},{"key":"42175","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2018.1506081","DOI":"10.1080\/09546634.2018.1506081"},{"key":"42176","doi-asserted-by":"crossref","unstructured":"Khemis A, Kelati A, Montaudi\u00e9 H, Lacour J-P, Passeron T. Successful treatment of severe psoriasis relapse with secukinumab (interleukin 17 A inhibitor) after abrupt brodalumab (interleukin 17 receptor inhibitor) discontinuation: a retrospective study evaluating long-term efficacy and safety. J Am Acad Dermatol 2018; 79: 758-760.","DOI":"10.1016\/j.jaad.2018.03.027"},{"key":"42177","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2018.03.027","DOI":"10.1016\/j.jaad.2018.03.027"},{"key":"42178","doi-asserted-by":"crossref","unstructured":"Georgakopoulos J, Phung M, Ighani A, Lam K, Yeung J. Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study. J Eur Acad Dermatol Venereol 2018; 33: e7-e8.","DOI":"10.1111\/jdv.15100"},{"key":"42179","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15100","DOI":"10.1111\/jdv.15100"},{"key":"42180","doi-asserted-by":"crossref","unstructured":"Hegazy S, Konstantinou M, Bulai Livideanu C, Tauber M, Paul C. Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab. J Eur Acad Dermatol Venereol 2019; 33: e338-e341.","DOI":"10.1111\/jdv.15630"},{"key":"42181","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15630","DOI":"10.1111\/jdv.15630"},{"key":"42182","doi-asserted-by":"crossref","unstructured":"Sherman S, Cohen ES, Amitay-Laish I, Hodak E, Pavlovsky L. IL-17A inhibitor switching-efficacy of ixekizumab following secukinumab failure. a single-center experience. Acta Derm Venereol 2019; 99: 769-773.","DOI":"10.2340\/00015555-3200"},{"key":"42183","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3200","DOI":"10.2340\/00015555-3200"},{"key":"42184","doi-asserted-by":"crossref","unstructured":"Deza G, Notario J, Lopez-Ferrer A, Vilarrasa E, Ferran M, Del Alcazar E, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol 2019; 33: 553-559.","DOI":"10.1111\/jdv.15288"},{"key":"42185","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15288","DOI":"10.1111\/jdv.15288"},{"key":"42186","doi-asserted-by":"crossref","unstructured":"Amschler K, Phillip S, Mohr J, Wilsmann-Theis D, Poortinga S, Gerdes S, et al. Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab. Dermatol Online J 2020; 26: 13030\/qt11d602x5.","DOI":"10.5070\/D3262047415"},{"key":"42187","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5070\/D3262047415","DOI":"10.5070\/D3262047415"},{"key":"42188","doi-asserted-by":"crossref","unstructured":"Enevold C, Loft N, Bregnh\u00f8j A, Zachariae C, Iversen L, Skov L, et al. Circulating brodalumab levels and therapy outcomes in patients with psoriasis treated with brodalumab: a case series. JAMA Dermatol 2022; 158: 762-769.","DOI":"10.1001\/jamadermatol.2022.1863"},{"key":"42189","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.1863","DOI":"10.1001\/jamadermatol.2022.1863"},{"key":"42190","doi-asserted-by":"crossref","unstructured":"Loft N, Bregnh\u00f8j A, Fage S, Nielsen CH, Enevold C, Zachariae C, et al. Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis. Dermatol Ther 2021; 34: e15106.","DOI":"10.1111\/dth.15106"},{"key":"42191","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.15106","DOI":"10.1111\/dth.15106"},{"key":"42192","doi-asserted-by":"crossref","unstructured":"Bonifati C, Morrone A, Cristaudo A, Graceffa D. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience. Dermatol Ther 2021; 34: e14584.","DOI":"10.1111\/dth.14584"},{"key":"42193","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.14584","DOI":"10.1111\/dth.14584"},{"key":"42194","doi-asserted-by":"crossref","unstructured":"Sherman S, Zloczower O, Noyman Y, Amitay-Laish I, Hodak E, Pavlovsky L. Ixekizumab survival in heavily pretreated patients with psoriasis: a two-year single-centre retrospective study. Acta Derm Venererol 2020; 100: adv00349.","DOI":"10.2340\/00015555-3714"},{"key":"42195","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3714","DOI":"10.2340\/00015555-3714"},{"key":"42196","doi-asserted-by":"crossref","unstructured":"Gniadecki R, Kragballe K, Dam T, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-1096.","DOI":"10.1111\/j.1365-2133.2011.10213.x"},{"key":"42197","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10213.x","DOI":"10.1111\/j.1365-2133.2011.10213.x"},{"key":"42198","doi-asserted-by":"crossref","unstructured":"Ahlehoff O, Skov L, Gislason G, Gniadecki R, Iversen L, Bryld L, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol 2015; 29: 1128-1134.","DOI":"10.1111\/jdv.12768"},{"key":"42199","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.12768","DOI":"10.1111\/jdv.12768"},{"key":"42200","doi-asserted-by":"crossref","unstructured":"Ahlehoff O, Skov L, Gislason G, Lindhardsen J, Kristensen SL, Iversen L, et al. Pharmacological undertreatment of coronary risk factors in patients with psoriasis: observational study of the Danish nationwide registries. PLoS One 2012; 7: e36342.","DOI":"10.1371\/journal.pone.0036342"},{"key":"42201","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0036342","DOI":"10.1371\/journal.pone.0036342"},{"key":"42202","doi-asserted-by":"crossref","unstructured":"Egeberg A, Iversen L, Gniadecki R, Hvid L, Dam T, Bryld L, etal. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis-nationwide results from the DERMBIO registry. J Eur Acad Dermatol Venereol 2017; 31: 1183-1187.","DOI":"10.1111\/jdv.14200"},{"key":"42203","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14200","DOI":"10.1111\/jdv.14200"},{"key":"42204","doi-asserted-by":"crossref","unstructured":"Loft N, Skov L, Bryld L, Gislason G, Egeberg A. Treatment history of patients receiving biologic therapy for psoriasis - a Danish nationwide study. J Eur Acad Dermatol Venereol 2017; 31: e362-e363.","DOI":"10.1111\/jdv.14156"},{"key":"42205","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14156","DOI":"10.1111\/jdv.14156"},{"key":"42206","doi-asserted-by":"crossref","unstructured":"Loft ND, Skov L, Rasmussen MK, Gniadecki R, Dam TN, Brandslund I, et al. Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis. PloS One 2018; 13: e0192010.","DOI":"10.1371\/journal.pone.0192010"},{"key":"42207","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0192010","DOI":"10.1371\/journal.pone.0192010"},{"key":"42208","doi-asserted-by":"crossref","unstructured":"Loft N, Skov L, Iversen L, Gniadecki R, Dam T, Brandslund I, et al. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. Pharmacogenomics J 2018; 18: 494.","DOI":"10.1038\/tpj.2017.31"},{"key":"42209","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/tpj.2017.31","DOI":"10.1038\/tpj.2017.31"},{"key":"42210","doi-asserted-by":"crossref","unstructured":"Gniadecki R, Bang B, Bryld L, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol 2015; 172: 244-252.","DOI":"10.1111\/bjd.13343"},{"key":"42211","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.13343","DOI":"10.1111\/bjd.13343"},{"key":"42212","doi-asserted-by":"crossref","unstructured":"Egeberg A, Ottosen M, Gniadecki R, Broesby-Olsen S, Dam T, Bryld L, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol 2018; 178: 509-519.","DOI":"10.1111\/bjd.16102"},{"key":"42213","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.16102","DOI":"10.1111\/bjd.16102"},{"key":"42214","doi-asserted-by":"crossref","unstructured":"Hesselvig JH, Egeberg A, Loft ND, Zachariae C, Kofoed K, Skov L. Correlation between dermatology life quality index and psoriasis area and severity index in patients with psoriasis treated with ustekinumab. Acta Derm Venereol 2018; 98: 335-339.","DOI":"10.2340\/00015555-2833"},{"key":"42215","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2833","DOI":"10.2340\/00015555-2833"},{"key":"42216","doi-asserted-by":"crossref","unstructured":"Loft ND, Egeberg A, Rasmussen MK, Bryld LE, Gniadecki R, Dam TN, et al. Patient-reported outcomes during treatment in patients with moderate-to-severe psoriasis: a danish nationwide study. Acta Derm Venereol 2019; 99: 1224-1230.","DOI":"10.2340\/00015555-3331"},{"key":"42217","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3331","DOI":"10.2340\/00015555-3331"},{"key":"42218","doi-asserted-by":"crossref","unstructured":"Gottlieb AB, Lacour JP, Korman N, Wilhelm S, Dutronc Y, Schacht A, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies. J Eur Acad Dermatol Venereol 2017; 31: 679-685.","DOI":"10.1111\/jdv.13990"},{"key":"42219","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.13990","DOI":"10.1111\/jdv.13990"},{"key":"42220","doi-asserted-by":"crossref","unstructured":"Chiricozzi A, Balato A, Conrad C, Conti A, Dapavo P, Ferreira P, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatol Treat Treatment 2020; 31: 476-483.","DOI":"10.1080\/09546634.2019.1671577"},{"key":"42221","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2019.1671577","DOI":"10.1080\/09546634.2019.1671577"},{"key":"42222","doi-asserted-by":"crossref","unstructured":"Mahil S, Wilson N, Dand N, Reynolds N, Griffiths C, Emsley R, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol 2020; 182: 1158-1166.","DOI":"10.1111\/bjd.18333"},{"key":"42223","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.18333","DOI":"10.1111\/bjd.18333"},{"key":"42224","doi-asserted-by":"crossref","unstructured":"Loft N, Egeberg A, Rasmussen MK, Bryld LE, Nissen CV, Dam TN, et al. Response to biologics during the first six months of therapy in biologic-na\u00efve patients with psoriasis predicts risk of disease flares: a Danish nationwide study. Acta Derm Venereol 2021; 101: adv00357.","DOI":"10.2340\/00015555-3722"},{"key":"42225","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3722","DOI":"10.2340\/00015555-3722"},{"key":"42226","doi-asserted-by":"crossref","unstructured":"Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C. Absolute and relative Psoriasis Area and Severity Indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis: an integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes. Acta Derm Venereol 2019; 99: 971-977.","DOI":"10.2340\/00015555-3245"},{"key":"42227","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3245","DOI":"10.2340\/00015555-3245"},{"key":"42228","doi-asserted-by":"crossref","unstructured":"Mason KJ, Barker JN, Smith CH, Hampton PJ, Lunt M, McElhone K, et al. Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatol 2018; 154: 581-588.","DOI":"10.1001\/jamadermatol.2018.0183"},{"key":"42229","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.0183","DOI":"10.1001\/jamadermatol.2018.0183"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/12616\/32768","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/12616\/32768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T13:53:24Z","timestamp":1700574804000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/12616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":80,"URL":"https:\/\/doi.org\/10.2340\/actadv.v103.12616","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,21]]}}}